Zhejiang Ausun Pharmaceutical (603229) Fundamentals 2026 — P/E 58.7x, Revenue Analysis | SniperIQ
Zhejiang Ausun Pharmaceutical (603229) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥6.5B, trading at ¥7.82 on the SHH. This SniperIQ fundamentals page covers Zhejiang Ausun Pharmaceutical's valuation (P/E 58.7x, P/B 2.7x), profitability (net margin 13.6%), revenue (¥787M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Ausun Pharmaceutical's market cap?
Zhejiang Ausun Pharmaceutical (603229) has a market capitalization of approximately ¥6.5B, trading at ¥7.82 on the SHH. Market cap moves with the live share price.
What is Zhejiang Ausun Pharmaceutical's P/E ratio?
Zhejiang Ausun Pharmaceutical's trailing twelve-month P/E ratio is 58.7x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Ausun Pharmaceutical?
Zhejiang Ausun Pharmaceutical runs a net profit margin of 13.6%, a gross margin of 53.0%, and an operating margin of 16.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Ausun Pharmaceutical generate?
Zhejiang Ausun Pharmaceutical reported revenue of ¥787M for fiscal year 2025, with net income of ¥131M and earnings per share (EPS) of 0.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Ausun Pharmaceutical pay a dividend?
Zhejiang Ausun Pharmaceutical offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Ausun Pharmaceutical financially healthy?
Zhejiang Ausun Pharmaceutical carries a debt-to-equity ratio of 0.25x and a current ratio of 2.64x, with a market beta of -0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Ausun Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Ausun Pharmaceutical (603229) the key facts are: market cap ¥6.5B, P/E 58.7x, revenue ¥787M, 52-week range 7.53-12.51. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Ausun Pharmaceutical's full fundamentals live
Get Zhejiang Ausun Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.